anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Arm 1: VAQTA™ 0.5 mL injection (2 doses 6 months apart), ProQuad™ 0.5 mL injection (2 doses 6 months apart), Prevnar™ 0.5 mL injection (one dose), all vaccines administered concomitantly. 28 weeks of study duration.
A prospective, open-label study in 10 healthy adults, ages 18-50, with abdominal scars will be pursued at the Clinical Research Unit at Wellman Center for Photomedicine (MGH). A side-by-side comparison of untreated vs. one topical treatment of ablative fractional photothermolysis in qualifying subjects will be made. Ten subjects will receive treatment on randomly-assigned portions of their scars, in addition to non-treated control sites. The primary measures of efficacy are (a) blinded evaluation of scar improvement from standard digital photographs taken before and after the treatments, (b) changes in scar volume (measured by 3D Image system) and/or scar width, and (c) a quantitative characterization of gene expression measured by mRNA expression levels from treated and untreated scars and control sites. The primary measures of side effects are inflammatory and pigmentary outcomes assessed by blind evaluation of digital photographs taken before and after the treatments. Another study endpoint includes histopathological examination and comparison of treated and untreated scars.

An FDA-approved 10600 nm Fractional laser source will be used for laser exposures performed 2 months prior to 2 skin biopsies (each 24 mm x 4 mm) of treated and untreated scar sites. A control site, with no treatment will also be left for clinical, histological and molecular examination.
Compsns. for treatment or prophylaxis of intestinal bacterial disturbances in poultry comprise at least one strain of intestinal anaerobic bacteria and an agent (I) which is nontoxic to the bacteria and reacts with any O2 present without producing any prod. toxic to the bacteria. The compsn. comprise frozen or freeze-dried cells and 0.05-0.3% of (I), which is a thiol, esp. cysteine. The compsn. also contain a nontoxic buffer to main a pH of 6-8, esp. 7.
This disclosure relates to methods and systems for detecting pace pulses in electrocardiogram (ECG) data. First ECG data associated with a first sampling frequency can be obtained. Candidate pace pulses in the first ECG data can be identified. Additional data comprising waveform descriptors characterizing the candidate pace pulses can be generated. Second ECG data can be generated by down-sampling the first ECG data. The second ECG data can be associated with a second sampling frequency that is lower than the first sampling frequency. Multiple ECG waveforms can be presented based on the second ECG data. The waveform descriptors characterizing candidate pace pulses can be presented based on the additional data.
RTA 744 injection administered intravenously for a maximum of 18 cycles (54 weeks). Dose escalation based on four dose levels and occurance of dose limiting toxicity (DLT).
All patients will be treated with the active product, Baricitinib. Each patient will take 4mg of Baricitinib daily for 36 weeks.
Patients should be informed of the following information beforeinitiating therapy with an NSAID and periodically during the course ofongoing therapy. Patients should also be encouraged to read theNSAID Medication Guide that accompanies each prescription dispensed

• Cardiovascular Thrombotic Events: Advise patients to be alert for the symptoms of cardiovascular thrombotic events, including chest pain, shortness of breath, weakness, or slurring of speech, and to report any of these symptoms to their health care provider immediately [see WARNINGS]. 

• IBU tablets, like other NSAIDs, can cause GI discomfort and, rarely,serious GI side effects, such as ulcers and bleeding, which mayresult in hospitalization and even death. Although serious GI tractulcerations and bleeding can occur without warning symptoms,patients should be alert for the signs and symptoms of ulcerationsand bleeding, and should ask for medical advice when observingany indicative signs or symptoms including epigastric pain, dyspepsia,melena, and hematemesis. Patients should be apprised of theimportance of this follow-up (see WARNINGS,Gastrointestinal Effects-Risk of Ulceration, Bleeding and Perforation). 

• IBU tablets, like other NSAIDs, can cause serious skin side effectssuch as exfoliative dermatitis, SJS and TEN, which may result inhospitalization and even death. Although serious skin reactions mayoccur without warning, patients should be alert for the signs andsymptoms of skin rash and blisters, fever, or other signs of hypersensitivitysuch as itching, and should ask for medical advice whenobserving any indicative sign or symptoms. Patients should beadvised to stop the drug immediately if they develop any type ofrash and contact their physicians as soon as possible.

• Heart Failure and Edema: Advise patients to be alert for the symptoms of congestive heart failure including shortness of breath, unexplained weight gain, or edema and to contact their healthcare provider if such symptoms occur [see WARNINGS]. 

• Patients should be informed of the warning signs and symptoms ofhepatotoxicity (e.g., nausea, fatigue, lethargy, pruritus, jaundice,right upper quadrant tenderness and “flu-like” symptoms). If theseoccur, patients should be instructed to stop therapy and seek immediatemedical therapy.

• Patients should be informed of the signs of an anaphylactoid reaction(e.g. difficulty breathing, swelling of the face or throat). If theseoccur, patients should be instructed to seek immediate emergencyhelp (see WARNINGS). 

• In late pregnancy, as with other NSAIDs, IBU tablets should beavoided because it may cause premature closure of the ductus arteriosus.
Within two months following CT scan, surgical mediastinoscopy will be performed to evaluate for the presence of mediastinal adenopathy. Each lymph node will be characterized according to published criteria. Staging will follow the TNM system of the AJCC. Patients with cytologically proven mediastinal lymph node metastases (N2 or 3), or those with mediastinal invasion of tumor (T4), will be treated according to standard clinical practice (typically chemotherapy and/or radiotherapy). All complications, morbidity, length of stay attributed to the diagnostic method (medical or surgical) used for staging will be recorded at 30 days, or at the time of surgery, whichever is first. All patients will will subsequently undergo surgical resection and complete mediastinal lymph node dissection.
Participants will be asked to limit all screen-based activities (television, smartphone, tablet, computer) for the first 72-hours following the initial clinic visit. After the first 72-hours following the initial clinic visit, participants will follow the standard of care as prescribed by their provider. No other specific recommendations will be made to participants regarding exercise, sleep, sedentary time, or physical activity.
Pediatric patients : It is difficult to recommend a maximum dose of any drug for pediatric patients since this varies as a function of age and weight. For pediatric patients of less than ten years who have a normal lean body mass and normal body development, the maximum dose may be determined by the application of one of the standard pediatric drug formulas (e.g., Clark's rule). For example, in pediatric patients of five years weighing 50 Ibs, the dose of lidocaine hydrochloride should not exceed 75-100mg when calculated according to Clark's rule. In any case, the maximum dose of lidocaine hydrochloride should not exceed 7 mg/kg (3.2 mg/lb) of body weight.

NOTE : Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever the solution and container permit. Solutions that are discolored and / or contain particulate matter should not be used and any unused portion of a cartridge of Lidocaine and Epinephrine Injections should be discarded.
The invention relates to a genetic engineering polypeptide vaccine for Myanmar subtype-containing 3 subtypes in an O-type foot and mouth disease virus, its preparation and application. According to the invention, 2 common Myanmar subtypes (Mya/7/2002, GenBank: DQ164928.1 and O/Mya/13/89, GenBank: DQ164924.1) and another common O-type foot and mouth disease subtype (Wuhan 2006, GenBank: DQ478936.1) in the O-type foot and mouth disease virus are selected. A DNA sequence of VP4 T-cell helper 15 amino acid fragments and DNA sequences of B cell determinants of 3 subtype VP1, as well as the DNA sequence of a universal sequence (CN: 201010199712.2) of the O-type foot and mouth disease virus are connected in series, and cloning is carried out without carrier protein for constructing 1 genetic engineering bacterium. And after high density fermentation, cell disruption, inclusion body renaturation, fusion protein separation and purification, as well as freeze-drying, an antigenic protein product can be obtained. The antigenic protein product and adjuvant homogenate can form the polypeptide vaccine, which contains polypeptides encoded by nucleotide sequences shown in SEQ ID and has the advantages of good safety and high potency. One-time immunization can cover the 3 common subtypes of the O-type foot and mouth disease virus, so that the polypeptide vaccine can be produced in large scale without pollution.
Malignant middle cerebral artery infarction (MMCI) has a fatality rate of up to 80%, due to massive brain edema, increased intracranial pressure, and cerebral herniation. The herniation-induced death usually occured during the first week, despite aggressive osmotherapy with mannitol or hypertonic saline, sedation, and eventually hyperventilation, buffers, or hypothermia. A growing evidence show that decompression craniectomy (DC) can produce a significant reduction in mortality rate and an improvement in neurological outcome, but the controversy of the DC still exists. There is an urgent need to find a more effective treatment method. Given that brain tissue necrosis-induced edema and cerebral herniation is the key reason of fatality and disability of MMCI patients, the investigators argue that the reduction of cerebral tissue volume by stereotactic infarct tissue aspiration (SITA) is likely to reach the decompression effect similar to the DC. Recently, the investigators performed SITA in 2 MMCI patients who were qualified for decompressive craniectomy, but refused by patient relatives, and their neurological function significantly improved.

The project is a prospective, randomized, single center, open label, clinical controlled trail. The eligible patients for enrollment are as follows: (1)ages from 40 to 90 years old; (2) malignant cerebral artery infarction within 48h onset; (3) craniotomy decompression can not be performed due to the contraindications, or refused by the patient or relatives. The patients are randomly assigned into 2 groups: (1) Medical therapy group: receiving osmotic therapy with mannitol and glycerol fructose，anti-platelet treatment, statins, and other symptomatic treatments such as controlling blood pressure, blood sugar, and infection, and tracheal intubation or incision, etc; (2) SITA group: receiving minimally invasive aspiration of infarct tissue 24-48 hours after stroke attacked on the basis of medical treatment. This study is aimed at comparing the efficacy and safety of of SITA in patients with MMCI.
Alopecia areata is a high prevalence autoimmune disease with significant consequences. Alopecia areata is a tissue restricted autoimmune disease directed at the hair follicle, resulting in hair loss. Patients frequently suffer severe psychiatric consequences. This is especially true of girls and young women who become bald. The incidence of alopecia areata in the USA (Minnesota is 20.2 per 100,000 person-years with a lifetime risk of approximately 1.7%. There is no significant gender difference. The disease is often chronic with a remitting, relapsing course. Although it responds to immunosuppression, generalized immunosuppression has significant morbidity and treatment is frequently frustrating and not successful. New treatment options are essential. With evidence that alopecia areata is a T-lymphocyte mediated autoimmune condition it has become a model system for the study of pathogenesis and treatment of T-cell mediated autoimmunity and as such is a model for a host of additional T-cell mediated autoimmune conditions.
The utility model relates to a medicinal plaster, which depends on effective agents by passing through human bodies to treat heart diseases, hyperosteogeny, etc. A veneering is composed of adhesive and spun laced non-woven fabrics. One side of the veneering is provided with a leakage prevention membrane whose periphery is provided with a prevention leakage ring; a medicine pad is positioned between the leakage prevention membrane and the leakage ring. The outside of the medicine pad is provided with one layer of mutual press type Kalaxin paper. The utility model is provide with profilogram which can be freely stretched and can suit to human bodies, having the advantages of strong air permeability, muting sensitive adhesive, exact dosage and long maintenance period; meeting water, the utility model does not fall off; the utility model does not dirty clothing easily. The utility model is suitable for treating diseases, such as heart diseases, hyperosteogeny, etc.
Patients apply fluorouracil intra-anally BID on days 1-5. Treatment repeats every 2 weeks for 8 courses in the absence of disease progression or unacceptable toxicity.
The invention provides a method for extracting antioxidant crocodile grease. Compared with the prior art, not only is the problem that the grease is easily oxidized solved, but also a potential safety hazard caused by adding of a synthetic antioxidant to the grease is avoided, and green, healthy and environment-friendly ideas are accorded. IC50 is the concentration of the required antioxidant when the removal rate is 50%, and frequently applied to comparison of the ability for removing DPPH.free radical, and the half maximal inhibitory concentration (IC50) is determined by drawing a curve according to the removal rate of different concentrations of antioxidants. The IC50 is smaller in value, which indicates that the oxidation resistance is stronger and the ability of removing free radical is stronger. The crocodile grease extracted by the traditional method (control group) is detected by adopting the DPPH method and compared with the grease product obtained in the embodiments 1,4 (experimental group) disclosed by the invention in the antioxidant activity; the determination result displays the crocodile grease IC50=24.920mg/mL extracted by the traditional method, a final grease product IC50=14.138mg/mL obtained by the embodiment 1, and the final grease product IC50=14.545mg/mL obtained by the embodiment 4. The antioxidant activity of the final crocodile grease product extracted by the Chinese herbal medicine soup is obviously improved.
The active component of XHANCE is fluticasone propionate, a corticosteroid, having the chemical name S-(fluoromethyl) 6α,9-difluoro-11β,17-dihydroxy-16α-methyl-3oxoandrosta-1,4-diene-17β-carbothioate, 17‑propionate and the following chemical structure:

Fluticasone propionate is a white powder with a molecular weight of 500.57, and the empirical formula is C25H31F3O5S. It is practically insoluble in water, freely soluble in dimethylformamide, sparingly soluble in acetone and dichloromethane, and slightly soluble in 96% ethanol.

XHANCE (fluticasone propionate) nasal spray, 93 mcg, for nasal administration, with an Optinose exhalation delivery system that delivers an aqueous suspension of microfine fluticasone propionate having a particle size distribution in the range of 0 to 5 microns for topical nasal administration by means of a metering, atomizing spray pump and exhaled breath. XHANCE also contains microcrystalline cellulose and carboxymethylcellulose sodium, dextrose, benzalkonium chloride, polysorbate 80, edetate disodium dihydrate, sodium hydroxide and hydrochloric acid (to adjust pH), and purified water, and has a pH between 5 and 7.

Before initial use, prime XHANCE by gently shaking and then pressing the amber glass bottle 7 times or until a fine mist appears. Once primed, XHANCE contains 120 metered sprays. When XHANCE has not been used for ≥ 7 days, prime again by releasing 2 sprays into the air, away from the face [see Dosage and Administration (2.2) and Instructions for Use].

After priming, each spray delivers 93 mcg of fluticasone propionate in an aqueous suspension through the cone-shaped nosepiece. The system also has a flexible mouthpiece. Within the device is a non‑removable amber glass bottle with a metering spray pump, an applicator, and a valve that prevents release of breath until the bottle is pressed. A base covers the bottom of the bottle, and a removable orange cap covers both the nosepiece and mouthpiece.
Analysis of the culture media of p40-transfected COS cells indicated the presence of 40 kDa monomers and 80 kDa disulfide-linked homodimers. Examination of partially purified p40 recombinant proteins demonstrated that only the homodimer but not the monomer binds to the IL-12 receptor. Partially purified 80 kDa homodimer inhibited [ 125  I]IL-12 binding to PHA-activated human lymphoblasts with an IC 50  of 80 ng/ml, which is similar to the IC 50  value (20 ng/ml) for the human IL-12 heterodimer. Although neither the 40 kDa monomer nor the 80 kDa dimer could stimulate human PHA-blast proliferation, the 80 kDa dimer inhibited IL-12-induced proliferation in a dose-dependent manner with an IC 50  of 1 μg/ml. The IL-12 p40 subunit contains the essential epitopes for receptor binding, but they are only active when p40 is covalently associated with a second protein such as p35 or p40. When p40 is associated with the p35 subunit, the heterodimer acts as an agonist mediating biologic activity. When p40 associates with itself, the homodimer behaves as an antagonist.
Intervention subjects will receive personalized cell phone reminder messages whenever they fail to take a dose within 30 minutes of dose time (as indicated by lack of a Wisepill opening). They will then participate in monthly interactive counseling sessions using summaries of their previous month's behavior. Patients whose mean adherence in the previous month was \<95% will be required to have a counseling session, while those with higher adherence will be given the option to have a counseling session.
The purpose of the present invention is to provide a detection agent (diagnostic agent) and a therapeutic agent which are taken into a tumor in the early stage of in vivo (in vivo) and which use c-KIT as a target molecule. As a result of studies on a molecular species to which c-KIT specifically binds and a labeling agent and a therapeutic agent binding to the molecular species, the present inventors have found that by combining a fragment of an anti-c-KIT antibody with IR700, tumor aggregation can be detected and treated in a short period of time of several hours after administration. Accordingly, the present invention relates to a complex of an antigen-binding fragment of an anti-c-KIT antibody and IR700, and also relates to a detection agent and a therapeutic agent each containing the complex as an active ingredient. Specifically, the present invention relates to a complex comprising an antigen-binding fragment of an antibody having a Complementarity Determining Region (CDR) in the heavy chain of an antibody comprising the amino acid sequence described in sequence No. 2, and a CDR in the light chain of an antibody comprising the amino acid sequence described in sequence No. 4, and IR 700.
The members of the conventional group had to complete pretest at the beginning of the study. Afterwards they had to take part at an interactive classroom based lecture about Advanced Life Support. The next step was the skills training with task trainers in order to teach them compression skills. Afterwards, the conventional group was divided into three blue code teams consisting of each 5 participants for the simulation session. Two independent instructors evaluated the video recordings in terms of technical and nontechnical skills. The final stage of the study were completing the post-test.
INTRODUCTION: Providing effective treatment for debilitating chronic pain is a challenge among many populations including military service members. Cognitive behavioral therapy for chronic pain (CBT-CP) is a leading psychological pain treatment. Pain catastrophizing is a pivotal mediator of pain-related outcomes. The purpose of this study was (1) to identify patient subgroups who differ in response to CBT-CP and (2) to explore the characteristics that define these patient subgroups. The overall goal was to obtain a better understanding of factors that may influence response to CBT-CP.
MATERIALS AND METHODS: This study was a secondary analysis of data from a clinical trial of 149 U.S. active duty service members with chronic pain. Participants underwent group-based CBT-CP for 6 weeks and completed pre- and posttreatment assessments. Finite mixture models were employed to identify subgroups in treatment response, with pain impact score as the primary outcome measure.
RESULTS: We identified two classes of nearly equal size with distinct pain impact responses. One class reported improved pain impact scores following CBT-CP. This improvement was significantly associated with lower (better) baseline depression scores and greater improvement in posttreatment pain catastrophizing. In contrast, the other class reported slightly worse mean pain impact scores following CBT-CP treatment; this response was not related to baseline depression or change in pain catastrophizing.
CONCLUSIONS: Our findings demonstrate that a sizable proportion of individuals with chronic pain may not respond to group-based CBT-CP and may require a more individualized treatment approach.
Randomized, prospective, controlled, blinded study of three-week inpatient rehabilitation and subsequent continuing of the training at home for 12 weeks. The control group received conventional rehabilitation without a specific training program. After 15 weeks training is also offered to patients in the control group.
PURPOSE:An antitumor agent containing an antitumor substance as an active ingredient comprising an extract of the root of a plant belonging to the genus Periandra as raw material. CONSTITUTION:An antitumor agent comprising an antitumor substance obtained by extracting the root of a plant such as leguminous shrub, etc. belonging to the genus Periandra, growing wild in the north and middle part of Brazil, with water or a hydrophilic organic substance (e.g., methanol, acetone, dioxane, etc.) at normal temperature or under heating as an active ingredient. The extracted antitumor substance absorbs slightly moisture and has good heat stability, so special attention is not required during pharmaceutical manufacturing. It is usually blended with a common excipein such as lactose, crystallite cellulose, magnesium stearate, corn starch, tableted, and used in the form of powder as it is. Suitable for oral administration, and a daily dose is 10-15mg/kg.